Hospira 2Q
2Q Revenues: $1.1 billion (+10%)
2Q Earnings: $144 million (+72%)
YTD Revenues: $2.1 billion (+5%)
YTD Earnings: $294 million (+30%)
Comments: Revenue growth in 2Q11 was driven primarily by sales of oncolytic docetaxel in the Specialty Injectables group. Sales for that unit were $675 million (+18%) in 2Q and $1.3 billion YTD (+11%). Sales for Other Pharma, which includes contract manufacturing, were down 5% for 2Q ($142 million) and down 10% YTD ($266 million).
Financial Reports: Hospira 2Q11
By Gil Roth
Published July 27, 2011
Related Searches:
Contract Manufacturing
•
contractpharma
•
contractpharma.com
•
Manufacturing
•
Pharma
•
blog comments powered by Disqus
